Substance Use Tools & Resources    

This NIDA web page includes facts and figures on prescription opioids.

This two-day public workshop convened regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines.

These estimated costs of opioid use disorder and fatal opioid overdose and their per capita costs at the state level can assist federal and state decision makers in understanding the magnitude of opioid use disorder and fatal opioid overdose in their jurisdictions.

This toolkit is tailored specifically to the unique needs of multidisciplinary substance use disorder (SUD) providers and programs serving perinatal individuals. It is meant to be a quick reference resource about mental health and SUD specific to perinatal individuals.

This guide provides considerations and strategies for clinicians and organizations implementing evidence-based practices. Approaches presented will assist clinicians, behavioral health organizations, primary care providers, insurers, and policy makers in understanding, selecting, and implementing evidence-based interventions that support adults with concurrent substance use and/or concurrent substance use disorders, including alcohol.

This toolkit is intended to give prescribers a broad overview of medication utilization management techniques and describe ways that prescribers can facilitate patient access to needed medications. It focuses on prescribed medications that are filled by retail pharmacies.

These reports and detailed tables present estimates from the 2019 National Survey on Drug Use and Health (NSDUH), specifically pertaining to substance use among women.

This research report provides information on the state of the science in the comorbidity of substance use disorders with mental illness and physical health conditions.

This guideline develops a framework to evaluate existing clinical practice guidelines for prescribing opioids for acute pain indications and recommends indications for which new evidence-based guidelines should be developed.

This report considers issues related to acute and chronic pain management and substance use disorders (SUD). It answers two guiding questions: (1) What are the priority gaps in QM science that need to be filled in order to reduce opioid use disorders (OUD